M
Meifang Han
Researcher at Huazhong University of Science and Technology
Publications - 59
Citations - 8246
Meifang Han is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Hepatitis B virus & HBsAg. The author has an hindex of 17, co-authored 55 publications receiving 6043 citations.
Papers
More filters
Journal ArticleDOI
Clinical and immunological features of severe and moderate coronavirus disease 2019.
Guang Chen,Di Wu,Wei Guo,Yong Cao,Da Huang,Hongwu Wang,Tao Wang,Xiaoyun Zhang,Huilong Chen,Haijing Yu,Xiaoping Zhang,Minxia Zhang,Shiji Wu,Jianxin Song,Tao Chen,Meifang Han,Shusheng Li,Xiaoping Luo,Jianping Zhao,Qin Ning +19 more
TL;DR: The SARS-CoV-2 infection may affect primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease in numbers as well as IFN-γ production, which may be of importance due to their correlation with disease severity in COVID-19.
Journal ArticleDOI
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.
Tao Chen,Di Wu,Huilong Chen,Weiming Yan,Danlei Yang,Guang Chen,Ke Ma,Dong Xu,Haijing Yu,Hongwu Wang,Tao Wang,Wei Guo,Jia Chen,Chen Ding,Xiaoping Zhang,Jiaquan Huang,Meifang Han,Shusheng Li,Xiaoping Luo,Jianping Zhao,Qin Ning +20 more
TL;DR: Severe acute respiratory syndrome coronavirus 2 infection can cause both pulmonary and systemic inflammation, leading to multi-organ dysfunction in patients at high risk, including patients with cardiovascular comorbidity.
Journal ArticleDOI
Acute liver failure: mechanisms of immune-mediated liver injury.
TL;DR: This review summarizes current concepts of immune‐mediated liver injury from both clinical studies and animal models and highlights immune responses of ALF from the liver injury perspective, which combines a variety of molecular and cellular mechanisms, particularly, the contribution of cytokines and the innate immune system.
Journal ArticleDOI
Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
Qin Ning,Meifang Han,Yongtao Sun,Jiaji Jiang,Deming Tan,Jinlin Hou,Hong Tang,Jifang Sheng,Mianzhi Zhao +8 more
TL;DR: For patients who achieve virological suppression with ETV, switching to a finite course of peginterferon alfa-2a significantly increases rates of HBeAg seroconversion and HBsAg loss.
Posted ContentDOI
Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019
Guang Chen,Di Wu,Wei Guo,Yong Cao,Da Huang,Hongwu Wang,Tao Wang,Xiaoyun Zhang,Huilong Chen,Haijing Yu,Xiaoping Zhang,Minxia Zhang,Shiji Wu,Jianxin Song,Tao Chen,Meifang Han,Shusheng Li,Xiaoping Luo,Jianping Zhao,Qin Ning +19 more
TL;DR: The SARS-CoV-2 infection may affect primarily T lymphocytes, particularly CD4+T cells, resulting in significant decrease in number as well as IFN-γ production, which may be associated with disease severity in COVID-19.